COVID-19 VACCINE NEWS
Special risk populations
MEDIA
COVID-19 PODCAST
Australia's Vaccine Agreements
-
Pre
Clinical -
Clinical
Phase I -
Clinical
Phase II -
Clinical
Phase III -
Post-Licensure Surveillance
Phase IV
Australia has entered into 5 agreements for the supply of COVID-19 vaccines. Details of these vaccines can be found below, noting that the University of Oxford/AstraZeneca and the Pfizer/BioNTech COVID-19 vaccines have been granted provisional registration from the TGA and are currently being rolled out within Australia. The Novavax COVID-19 vaccine candidate is still in phase III clinical trials and will only be supplied if it is proved safe and effective and meets the strict criteria for registration by the TGA. The Moderna COVID-19 vaccine is currently in use internationally, with supply to Australia anticipated in the later part of 2021, following approval by the TGA.
COVAX Facility
The COVAX Facility is a global initiative designed to support rapid, fair and equitable access to COVID-19 vaccines. It allows all participating countries, regardless of income levels, to have equal access to a portfolio of vaccines once they have been developed. COVAX is coordinated by Gavi with help from member countries, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization and UNICEF.
